Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722011 | 1.00 | HPGD (0.50) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL5770967 | 0.90 | HPGD (0.50) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL5931015 | 0.90 | HPGD (0.50) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL22955531 | 0.88 | HPGD (0.50) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL20519800 | 0.88 | HPGD (0.50) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL20519803 | 0.88 | HPGD (0.50) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL743795 | 0.85 | EPHX1 (0.49) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL743796 | 0.85 | EPHX1 (0.49) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL6315997 | 0.84 | NR1H2 (0.46) | HPGDGPR119RECQLEPHX1USP2 | |
| SCHEMBL6316000 | 0.84 | NR1H2 (0.46) | HPGDGPR119RECQLEPHX1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308931-A1 | LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE | 2024-09-19 | — | — | US | disclosed |
| EP-4370490-A1 | LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS | The Scripps Research Institute (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023287964-A1 | LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287964-A1 | LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11485725-B2 | Derivatives of piperlongumine and uses thereof | AURANSA INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2019103897-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| EP-1585749-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| WO-2004063198-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| US-6384028-B1 | TREATMENT OF CARDIOVASCULAR DISORDERS, ANTICOAGULANTS AND VALVE REPLACEMENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| US-6265418-B1 | ANTICOAGULANTS | UBE INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0869944-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| WO-1996029309-A1 | N-ACYLPIPERIDINYLCARBONYLAMINOCARBOXYLIC ACIDS AND THEIR USE AS GLYCOPROTEIN IIB/IIa ANTAGONISTS AND FIBRINOGEN-BLOOD PLATELETS BINDING INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308931-A1 | LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS | PPARD, PPARA, PDCD1LG2 | HPGD 255/4885GPR119 966/4885RECQL 4803/4885 |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | SHARPIN, PIR, THPO | HPGD 285/4885GPR119 2054/4885RECQL 4506/4885 |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | HPGD 2297/4885GPR119 1628/4885RECQL 566/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | HPGD 1448/4885GPR119 86/4885RECQL 2539/4885 |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | HPGD 73/4885GPR119 3008/4885RECQL 4108/4885 |
| US-11485725-B2 | Derivatives of piperlongumine and uses thereof | PIR, THPO, DHPS | HPGD 82/4885GPR119 3240/4885RECQL 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.